RT Journal Article
SR Electronic
T1 EPV149/#132 Performance characteristics of brief family history questionnaire to screen for lynch syndrome in women with newly diagnosed ovarian cancers
JF International Journal of Gynecologic Cancer
JO Int J Gynecol Cancer
FD BMJ Publishing Group Ltd
SP A89
OP A89
DO 10.1136/ijgc-2021-IGCS.219
VO 31
IS Suppl 4
A1 RS Kim
A1 A Tone
A1 R Kim
A1 M Cesari
A1 L Eiriksson
A1 T Hart
A1 A Lytwyn
A1 M Maganti
A1 M Bernardini
A1 A Oza
A1 B Djordjevic
A1 J Lerner-Ellis
A1 E Van De Laar
A1 D Vicus
A1 A Pollett
A1 S Ferguson
YR 2021
UL http://ijgc.bmj.com/content/31/Suppl_4/A89.1.abstract
AB Objectives Ovarian cancer (OC) is the third most common Lynch syndrome (LS)-associated cancer in women but there is no established screening strategy to identify LS in this population. We have previously validated the 4-item brief Family History Questionnaire (bFHQ) in endometrial cancers. The objective of this study was to assess whether bFHQ can be used as a screening tool to identify women with OC at risk of LS.Methods In this multicenter prospective cohort study, women with OC completed bHFQ, extended Family History Questionnaire (eFHQ; encompassing Amsterdam II criteria, Society of Gynecologic Oncology 20–25% criteria and Ontario Ministry of Health criteria), immunohistochemistry (IHC) for mismatch repair (MMR) proteins and universal germline testing for LS. Performance characteristics were compared between bFHQ, eFHQ, and IHC.Results of 215 participants, 169 (79%) were evaluable with both bFHQ and germline mutation status; 12 of these 169 were confirmed to have LS (7%). Nine of 12 patients (75%) with LS were correctly identified by bFHQ, compared to 6 of 11 (55%) by eFHQ and 11 of 13 (85%) by IHC. The sensitivity, specificity, positive predictive values and negative predictive values of bFHQ were 75%, 66%, 15% and 98%. The 4-item bFHQ was more sensitive than eFHQ and took less than 10 minutes for each patient to complete.Conclusions Patient-administered bFHQ may serve as an adequate screening tool to triage women with OC for further genetic assessment for LS, especially in centers without access to universal tumor testing for IHC for MMR.